Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy  

作　　者：Yingying Li Shiyuan Wang Mengmeng Lin Chunying Hou Chunyu Li Guohui Li 

机构地区：[1]Pharmacy Department,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

出　　处：《Frontiers of Medicine》2022年第3期307-321,共15页医学前沿（英文版）

基　　金：supported by Bijing Hope Run Special Fund of Cancer Foundation of China(No.LC2020L03)and Bejig Municipal Science&Technology Commission(No.Z1811000-01618003).

摘　　要：The discovery of immune checkpoint inhibitors,such as PD-1/PD-L1 and CTLA-4,has played an important role in the development of cancer immunotherapy.However,immune-related adverse events often occur because of the enhanced immune response enabled by these agents.Antibiotics are widely applied in clinical treatment,and they are inevitably used in combination with immune checkpoint inhibitors.Clinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpoint inhibitors.Studies have shown that the gut microbiota is essential for the interaction between immune checkpoint inhibitors and antibiotics,although the exact mechanisms remain unclear.This review focuses on the interactions between immune checkpoint inhibitors and antibiotics,with an in-depth discussion about the mechanisms and therapeutic potential of modulating gut microbiota,as well as other new combination strategies.

关 键 词：tumor immunotherapy immune checkpoint inhibitor ANTIBIOTICS gut microbiota drug–drug interaction 

分 类 号：R73[医药卫生—肿瘤] R978.1[医药卫生—临床医学]